A PHASE 1/2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 2-PART STUDY OF THE SAFETY, TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE DOSE ALN-6400 IN ADULT HEALTHY VOLUNTEERS AND MULTIPLE DOSE ALN-6400 IN ADULT PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)

Registry ID

ALN-6400-001

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

ALNYLAM PHARMACEUTICALS INC

Start date

2026-01-02

Last update

2024-10-17

Conditions

• HEREDITARY HAEMORRHAGIC TELANGIECTASIA

Related clinical trials

• DOXYCYCLINE CROSSOVER TRIAL FOR HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)

View on source registry